How to Design SUSAR Detection & Expedited Reporting That Meets FDA, EMA and MHRA Expectations

Published on 22/11/2025

How to Design SUSAR Detection & Expedited Reporting That Meets FDA, EMA and MHRA Expectations

In the landscape of clinical trials, ensuring patient safety is paramount. One of the critical facets of this responsibility is the detection and reporting of Suspected Unexpected Serious Adverse Reactions (SUSARs). This tutorial serves as a comprehensive guide for clinical operations, regulatory affairs, and medical affairs professionals in the United States, United Kingdom, and European Union on how to design effective SUSAR detection and expedited reporting systems that align with the expectations of the FDA, EMA, and MHRA.

Understanding SUSARs and Regulatory Requirements

Before delving into the specifics of designing a SUSAR detection and reporting system, it is essential to comprehend what SUSARs are, alongside the relevant regulatory expectations set forth by the FDA, EMA, and MHRA. A SUSAR is defined as an event that is both serious and unexpected, typically occurring in connection with the use of an investigational medicinal product.

The FDA outlines the importance of SUSAR reporting in Title 21 of the Code of Federal Regulations (CFR), particularly in §312.32, which stipulates that investigators must report to the sponsor all serious adverse events (SAEs) and their suspected causal relationship with the drug under investigation.

In the EU, the EMA provides similar guidance under the Clinical Trials Regulation (EU) No. 536/2014, which emphasizes timely reporting of SUSARs, specifically within 7 days of first knowledge by the sponsor, followed by a detailed report within 15 days.

The MHRA also adheres to these international standards and mandates that serious adverse events must be reported if they are unexpected and relate to an investigational medicinal product as outlined in their Standard Operating Procedures.

Step 1: Establishing a Framework for SUSAR Detection

The first step in designing a SUSAR detection system involves creating a robust framework that aligns with regulatory guidelines and best practices in clinical research. Here’s how to structure that framework:

1.1 Define Roles and Responsibilities: Clearly outline who is responsible for monitoring, detecting, and reporting SUSARs within your clinical trial framework. This includes roles such as the Principal Investigator, Clinical Research Associates, and Data Monitoring Committees.
1.2 Implement Effective Adverse Event Tracking: Utilize clinical trial management systems (CTMS) that facilitate real-time tracking and documentation of adverse events. This will ensure timely identification of potential SUSARs.
1.3 Conduct Training and Awareness Programs: Regular training sessions for clinical staff regarding the definition of SUSARs and the protocols for detection. Awareness of how to differentiate between expected and unexpected events is critical.
1.4 Utilize Data Analytics: Leverage data analytics tools to monitor adverse events and detect patterns. Using advanced analytics can aid in identifying trends that may suggest a SUSAR.

Step 2: Developing a SUSAR Reporting Process

Once you have established a detection framework, the next step is to develop a streamlined reporting process to ensure timely and accurate reporting of SUSARs. The following are crucial components:

2.1 Create Clear SOPs: Develop Standard Operating Procedures (SOPs) that delineate the steps for reporting a SUSAR, including timelines, necessary forms, and data required. Ensure these SOPs comply with FDA, EMA, and MHRA regulations.
2.2 Ensure Centralized Reporting: Establish a centralized reporting system that allows all investigators to submit SUSAR reports uniformly. This process should facilitate immediate communication with the sponsor and regulatory authorities.
2.3 Incorporate Electronic Reporting Systems: Utilize electronic databases and reporting tools that comply with regulatory standards to reduce the time taken for report generation and submission.
2.4 Maintain an Audit Trail: Ensure that the reporting process includes an audit trail of all submissions to allow for traceability and accountability. This step is necessary for regulatory inspections and compliance checks.

Step 3: Ensuring Compliance with Regulatory Timelines

Compliance with reporting timelines is an essential aspect of SUSAR management. Each regulatory body necessitates specific timelines within which SUSARs must be reported:

3.1 FDA Requirements: The FDA requires that a SUSAR be reported within 7 days of initial knowledge, followed by a comprehensive report within 15 days. It’s crucial to develop a system that can log events promptly to meet these deadlines.
3.2 EMA Requirements: The EMA’s guidelines dictate a similar framework, requiring reporting within 7 days for initial reports and 15 days for follow-ups. Developing a calendar or reminder system can help in maintaining compliance.
3.3 MHRA Notifications: The MHRA also adheres to the 7/15-day reporting schedule, emphasizing that timelines should be integrated into your tracking system.

Step 4: Quality Assurance and Continuous Monitoring

To maintain high standards of SUSAR detection and reporting, quality assurance and continuous monitoring must be integrated into your protocol:

4.1 Conduct Periodic Audits: Regular audits of the SUSAR detection and reporting processes can help identify gaps and areas of improvement. This practice promotes transparency and compliance.
4.2 Encourage Feedback Mechanisms: Create channels for investigators and staff to provide feedback on the SUSAR processes. This can lead to refinements in procedures and improved understanding.
4.3 Perform Root Cause Analysis: When SUSARs occur, conduct a root cause analysis to ascertain underlying issues that may have contributed to the occurrence. This information can guide future preventative measures.
4.4 Stay Updated on Regulatory Changes: Regulatory guidelines are subject to change. Regular training sessions and updates for the clinical operational team should be instituted to ensure they remain informed on the latest regulatory expectations.

Step 5: Communication with Stakeholders

Effective communication with all stakeholders—including investigators, sponsors, and regulatory authorities—is vital in the context of SUSAR management. The key steps include:

5.1 Establish Regular Communication Plans: Create timelines for regular updates with stakeholders about SUSAR discussions, findings, and resolutions.
5.2 Strengthen Investigator-Sponsor Relationships: Foster open communication between investigators and sponsors regarding the detection of adverse events. This can enhance trust and prompt reporting of potential SUSARs.
5.3 Engage with Regulatory Bodies: When required, engage with regulatory bodies to discuss SUSAR cases, especially if a significant emerging trend is recognized.
5.4 Document Communication: All communications regarding SUSARs should be well-documented for future reference and regulatory scrutiny.

Step 6: Leveraging Technology in SUSAR Management

The integration of technology in SUSAR management can optimize detection and reporting processes, especially for complex trials such as non-small cell lung cancer clinical trials, or trials like the AEGEAN clinical trial or the MARIPOSA clinical trial. Technology utilization entails:

6.1 Employing Electronic Data Capture Systems: Utilize Electronic Data Capture (EDC) systems to enhance data collection for SUSAR events. These systems facilitate real-time data access and can simplify the reporting process.
6.2 Implementing AI-driven Tools: Explore artificial intelligence tools that can annotate adverse event reports and flag potential SUSARs based on historical data patterns. This can reduce the burden on clinical staff and improve detection accuracy.
6.3 Utilizing Real-World Data: Analyze real-world data for insights into adverse events that may not be captured in clinical trials. This is particularly relevant in trials involving complex therapeutic areas.
6.4 Automating Follow-up Processes: Automate follow-up tasks for SUSAR monitoring and reporting to streamline workflows and decrease manual errors, thereby enhancing compliance.

Conclusion

Designing an effective SUSAR detection and expedited reporting system is essential to safeguarding participants in clinical trials and ensuring compliance with regulatory expectations. By establishing a robust framework, developing clear SOPs, ensuring compliance with timelines, implementing quality assurance measures, facilitating communication with stakeholders, and leveraging technology, clinical operations, regulatory affairs, and medical affairs professionals can enhance the overall management of SUSARs. In an era where participant safety is paramount, it’s crucial to uphold high standards of vigilance and diligence in all clinical trial processes.

Adopting these step-by-step methodologies will not only streamline SUSAR detection and reporting processes across msa clinical trials but also fortify the integrity of clinical research as a whole. For further information regarding the principles of Good Clinical Practice as it relates to adverse event reporting, refer to the ICH Guidelines which provides a fundamental framework for implementing these practices globally.